Dr Agarwals Eye Hospital enterprise value

Share price at each year-end

Tap a line for its trend	Currentlast close	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus


2,405	—	—	—	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
95.7	95.7	25.2	32.9	27.4
81.8	81.8	96.4	51.3	43.8
2,391	—	—	—	—
−13.9	−13.9	71.2	18.4	16.5
₹5,015.39	—	—	—	—

428	428	306	208	157
19.1%	19.1%	31.5%	24.6%	27.9%
0.03×	—	—	—	—

5.08×	—	—	—	—
16.46×	—	—	—	—
23.99×	—	—	—	—
471	471	397	319	268
145	145	119	91.1	74.7
99.7	99.7	79.1	64.5	54.5
—	—	94.5	89.8	69.6
—	—	94.5	89.8	69.6

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

DRAGARWQ₹5,044.50

Dr Agarwals Eye Hospital Limited

· Pharma & Health

₹ CrorePeersKMCSHIL KOVAI LOTUSEYE GPTHEALTH GKSL SHALBY INDRAMEDCO ARTEMISMEDMcap ₹2,405 Cr

HighlightsEnterprise Value Multiples Per ShareAnnuals · FY-end closes

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Current last close
Market Capitalization	—	—	—	—	2,405.2
- Cash, Equiv & ST Investments	27.4	32.9	25.2	95.7	95.7
+ Total Debt	43.8	51.3	96.4	81.8	81.8
Enterprise Value	—	—	—	—	2,391.4
Net Debt (memo)	16.5	18.4	71.2	-13.9	-13.9
EV per Share	—	—	—	—	5,015.39

Total Capital	157.2	208.5	306.0	428.1	428.1
Total Debt/Total Capital	27.89	24.61	31.49	19.11	19.11
Total Debt/EV	—	—	—	—	0.03

EV/Sales	—	—	—	—	5.08
EV/EBITDA	—	—	—	—	16.46
EV/EBIT	—	—	—	—	23.99
Reference Items — Trailing FY Values
Sales	267.9	319.3	397.2	470.9	470.9
EBITDA	74.7	91.1	118.5	145.3	145.3
EBIT	54.5	64.5	79.1	99.7	99.7
Operating Cash Flow	69.6	89.8	94.5	—	—
Free Cash Flow	69.6	89.8	94.5	—	—

Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.